■■ ColorectalCancer Epidemiology
Every7seconds,someone turns50years old; every 3.5minutes, someoneisdiagnosed with CRC; every 9minutes,someone dies from CRC; andevery 5seconds,someone whoshould be screened forC RC is not. The5 -yearm ortality forp eopled iagnosed with CRCi sa pproximately 40%; however, survival improves substantiallyi ft he canceri sd iagnosed whilei ti ss till localized. In at ypical generalp racticewith5 00 patients older than 50 years, onew ould expect 100t o2 50 of thesepatientst ohave colorectal adenomas.T en to thirty of thesep atientsw ould be expected to have CRC, andb ecause only onet hird area pt to be screened, twothirdsofthese patients maydie unnecessarily. Unfortunately, 20%ofCRC patients whodoreceive screening maybediagnosed in thelater,less-treatable stages. 2 Theg ood newsi st hatC RC's incidencer ated eclined by 2.9% annuallyf rom1 998t o2 001. Regardless,c olorectal cancer remainst he thirdm ost common canceri nm en andw omen in theU nitedS tates. 3 Thed eclineinincidence mayhave been due, in part,t oincreased screeningand polypr emoval.T he National CancerI nstitute's Surveillance,E pidemiology andE nd Results (SEER)Program monitors theincidence of allcancers throughout theU nitedS tates. Forb othm en andw omen,t he incidenceo f CRCbeginstorisearoundthe ageof40years.Incidence sharply increasesatage 50 years;9 2% of CRCs arediagnosed in persons aged 50 years or older. People in their80s clearlyc ontinue to be at risk forC RC,w ith1 2.5% of casesd iagnosed aftera ge 85. 2, 3 Because ageisasignificant risk factor andthe American population is aging, thepopulationofindividuals at risk forCRC is larger thanithas everbeen.
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BaCkgrOund:Every 3.5 minutes,someoneisdiagnosed with colorectal cancer (CrC); every9minutes,someonediesfromCrC;and every 5seconds, someonewho should be screened forCrC is not. The5-year mortalityfor peoplediagnosed with CrCisapproximately 40%; however, survival improves substantially if thecancer is diagnosed whilestill localized.
OBjECTIvE: To track and review therapid progress researchers have made in CrC.
SuMMary: amongpatientswho have CrC, approximately 50%will eventually developliver metastases.The oncologyfield'ssignificant advancesinthe last fewyears,especiallyinCrC, challengeclinicians and patients. Multiplefacets of care intersectinCrC:medical management,pharmacymanagement,symptommanagement,casemanagement, and patient advocacy.CrC develops over many yearsasenvironmental and geneticfactors interact.The american CancerSociety recommends screening allmen and womenolder than 50 yearsand thoseathighrisk at an earlierage.Inthe past,patientspresenting with thesamestage of CrCwereconsidered similar. Thestaging criteriaofthe american joint Committee on Cancerrecognizesthatsubsets of patients with varying survival statisticscan be identified and that each patient requires a strategicapproach. Theu.S. Food and drugadministration approval of irinotecan in 1996 and oxaliplatinin2002changed thelandscape, and ultimately,the oral agentcapecitabineand thebiologicsbevacizumab and cetuximabalsosignificantlyexpanded treatmentoptions.
Itsp revalencea nd preventablen aturem akes CRCap rimary focusinthe oncologycommunity.Infact, estimatesindicatethat gastrointestinal cancers representa bout 20%o fall cancers.T he broadd iversity in thet ypes of patients ands tagesa tw hich thedisease is diagnosedcreates multidisciplinarychallenges.
Amongp atientsw ho have CRC, am ajority will eventually developliver metastases.In30% to 40%ofCRC patients,metastases areconfined to theliver when they areinitiallyfound.One quartertoone thirdofpatientswh oare able to undergo resection of liverm etastases will live 5y ears or longer;m edian survival afterr esectioni sb etween 24 and4 0m onths. This highr ateo f livermetastases has transformed treatmentand evaluation in an effort to improvecurerates. 5 More recentdataindicatethatsurvivalrates maybeincreasing. [6] [7] [8] Ther iskf actors forC RC forp eoplew ho live in theU nited States arep resentedi nT able 1. CRCd oesn ot discriminate by gender or ethnicityi nt erms of incidenceo rm ortality. Socioeconomic groups in thel ower income ranges tend to presentwithm orea dvanceddisease.M en tend to develop CRC slightly more oftent hanw omen. 2 Thed isease affectsa ll ethnic groups,a nd epidemiologics tudies confirm thate nvironmental exposure is probably af actor. Fore xample,p eoplew ho immigrated to theU nited States from Japan-where CRCw as once al ow-incidence disease-eventuallyd eveloped CRCa tar ate similart on ative-born Americans. Today, Japan's incidenceo f CRCi sr isingd ramatically, probably duet oW estern influence, particularly in diet;dietaryintakeofmilk,meat, eggs,and fat/oil increasedremarkablyinJapan from 1950 to 1970,and it remains at this elevated levelt oday. 9 Globally,s omed ifferencesi ni ncidencer emainr elated to location andl ow socioeconomic status. Japan's experience supports what we know:diet is aleading risk factor forCRC.
CRCi sc onsidered ac ompletelyp rev entabled isease b ym ost experts, andt he fact thatm anyo fi ts risk factorsa re relatedt o lifestyle reflect thatb elief. High-fat dietsw ithf ew fruits and vegetables,inactivity, obesity, smoking, andalcoholuse increase risk.Interestinchemoprevention is high,and trials suggestthat nonsteroidal anti-inflammatorydrugs (NSAIDs, such as ibuprofen) andcyclooxygenase-2 (COX-2)inhibitors( such as rofecoxib or celecoxib) mayreducethe risk of CRC. TheCRC-related mortality hasbeenreduced 40%to50% in individualswho regularly take aspirina nd otherN SAIDs. Additionally,C OX-2 is elevated in 85%t o9 5% of CRCs;o verexpressionh as been shownt o decrease cancerc elld eath. 10, 11 Ones tudy of aC OX-2 inhibitor (celecoxib)showedasignificantreduction in polyps. [12] [13] [14] Approximately7 0% of CRCs aren onhereditary,o rs poradic, anda bout 20%a re familial.T wo keyh ereditarys yndromes are familial adenomatouspolyposis (FAP)and hereditary nonpolyposis colonc ancer( HNPCC).T he FAPs yndromed evelopsf rom inheritedm utations of thea denomatousp olyposis coli (APC) gene,and accounts forapproximately 1% to 2% of allCRC cases. Patientsw ithF AP develop hundreds to t housandso fp olyps before age30, andinevitably develop CRC. Usually, CRCd evelopsatanearly age( average,39years)inF AP patients,but it can be prevented by surgicallyremovingthe colon. 15 Lynchs yndrome, or HNPCC, is causedb yi nheritedm utation in any1o f5m ismatchr epair( MMR)g enes,a nd accounts for3 %t o5 %o fall CRCcases.T he term nonpolyposis does not mean that thec ancerd oesn ot emanatef romp olyps; it is used to distinguishH NPCC from FAP. Polyps do notd evelop earlier in people with HNPCC, buto ncet heyd o, theirt endencyt o become malignantm orer apidlyl eads to a7 0% to 80%l ifetime risk of CRC. In thesep atients, CRCo ccursa tearly age( average 44 years).S omep atientsw ithH NPCC also elect to have a complete colectomyb ecause of theiri ncreased risk of rapid developmentofcolon cancer. Expertsstress theneedfor detailed family historyt oi dentifyi ndividuals whoa re at risk top rovide appropriate screening, geneticc ounseling, andt reatment. It has been recommendedthatp eoplew ho have af irst-degreer elative whoh as had CRCs houldb es creeneda nnuallyb eginninga t age4 0, rather than at age5 0. Family memberso fp atientsw ho developedCRC very early(i.e.,beforeage 50)shouldbescreened 10 yearsb eforet he agea tw hich ther elatived eveloped CRC. Fore xample,i fap atient's brother, or otherf irst-degreer elative, developed CRCa ta ge 45,the patients houldb egin screeninga t age3 5. Epidemiology,DiseaseProgression,and EconomicBurdenofColorectalCancer arec onsidered premalignant. Polyps larger than2c mi nd iameter have a50% chance of becoming malignant. Polypremoval, althoughnot perfect, dramaticallyreduces theincidence of colorectal cancer. Previous CRCincreases risk foranew primarytumor at least4 -fold; therefore, regulars creening with colonoscopy becomesal ifelongr equirementf or thesep atients. In addition, people with inflammatoryb owel disease,p articularlyulcerative colitisa nd Crohn's disease, must be screenedv eryc arefully because of theirsubstantialriskofdevelopingcancer. [19] [20] [21] Ouru nderstanding of them olecular biologyo fc olon cancerh as growne xponentiallyi nr ecenty ears.C olorectal cancer develops over many yearsa se nvironmental andg enetic factors interact.Environmentally,ahigh-fatdiet playsaroleinthe development of CRC, especially in thedescendingand sigmoidcolon. Fatm akes up 40%t o5 0% of totalc aloric intake in Western countries. 9 Animalsf ed high-fat dietsd evelop more carcinogeninducedc olonc ancers than do animals o nl ow-fat diets. 22, 23 Dietaryfatsare convertedintopotentiallycarcinogenicsubstances ande nhancec holesterola nd bile acid synthesisb yt he liver. Bacterialfloraconvert thesecompoundstosecondary bile acids, cholesterolm etabolites,a nd otherp otentiallyt oxic metabolites. Bile acidsm ay activate proteink inaseC -ane nzymei nvolved in thetransferofcellsignals that,whenactivated,induceexcess cellular production. 24 Colorectal cancera risesa sg enetic alterationst hatc ause abnormal cellular proliferation, resultingi np rogressionf rom normal colonicm ucosat oa denomas or adenomatousp olypst o adenocarcinoma. This progressioncan be inducedbyaserieso f inherited or noninherited mutationsi nvolving oncogenes and tumorsuppressor genes. Inherited APCand MMR mutationsare responsible fort he 2m ost common typeso fh ereditaryC RC. Theseg enes area lsoi nvolvedi nn oninherited mutations, along with Kirsten-ras( K-ras),p 53,a nd otherg enes.N oninherited mutationso ft he APCg enea re also presenti n6 0% to 80%o f sporadicCRC andadenomas.
•h MLH1 is theMMR gene most commonly mutatedinsporadic
CRCs,e speciallyt hose occurringi nt he righto rt ransverse colon.
•K -ras is an importantp roto-oncogeneinvolvedinthe regulation of cell proliferation. K-rasmutations arepresent in about 40%ofCRCs.
•p 53 is atumor suppressor gene normallyinvolvedinpreventing cellsw ithd amaged DNAf romp rogressingt hrought he cell cycle. This gene also inhibits angiogenesis,possiblybydecreasinge xpressiono fv asculare ndothelial growth factor (VEGF). Loss of p53i sp resent in approximately7 5% of CRCa nd is involvedinthe conversion of adenomatoadenocarcinoma. 21 Thesequence of moleculareventsisnot alinear, butrathera collectionofeventsthatoccursovertime. Usinglarge tumorbanks (repositoriesfor tissue specimens),researchers maysomeday link coloncancerclinicaltrial efficacy data to develop both prognostic andpredicted strategies basedonthe tumor'smolecular biology. This information will allow clinicianst ofine-tune thea pproach foreachindividual patient. Managed care pharmacistsm ay be unfamiliar with cancer terminologyingeneral,and treatment of CRCspecifically. Table3 defines some termsn ecessaryt ou nderstandr ecentc hanges in itsd iagnosis andt reatment. Surgeryh as always been the treatmento fc hoice forCRC.Radiation generallyisr estrictedt o rectal cancers.A dditionally, readers should keep in mind that untilt he mid-1990s,c hemotherapyf or CRCw as limited to leucovorin andf luorouracilc ombinations. TheU .S.F ood and Drug Administration (FDA)a pprovalo fi rinotecan in1 996 ando xaliplatin in 2002 changedt he landscape, andu ltimately, theb iologics bevacizumaba nd cetuximaba lsos ignificantly expandedt reatment options. Oncology is also af ield thatu ses many (and sometimesc onfusing)a cronyms. These, too, are addressed in Table3 .S ometimes,c linicians, researchers,o r institutions modify standard regimens,and they arethengiven a similarbut newname( e.g.,FOLFOX4,FOLFOX6).
■■
Them ost common treatmentf or pat ientsw ithl ocalized CRCi ss urgery,w hich is frequentlyc urative. Althougha djuvant chemotherapy in stageI Id isease hasb eeni nvestigated,i ts use remainsc ontroversial,w itho verall survival rangingf rom approximately7 5% to 80%w iths urgery alone. Surgerya nd adjuvant chemotherapy arec ommont reatmentsf or patients with stageI II disease. Conversely,t he overall survival among individualswithstage IIICcolon cancer, even aftersurgicalresection,i sa sl ow as 15%. Thed ifferencesi ns urvivala re striking. Combinationchemotherapyisgiven formetastaticdisease when possible.C hemotherapywithr adiation is givenb efore( favored) or aftersurgery in most patients with stageIIorIII rectal cancer. Thus,one strategy forall patients is inappropriate. 25 Case 1intro-ducesthese issues (see Sidebar1 ).
Fortunately, guidance is available forc linicians. TheN CCN has createdtreatment guidelines foralmost everycancerand for themost common treatment-inducedsymptoms.
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Allare available online at www.nccn.org. Thec olonc ancerg uidelinesa re currentlyunder evaluation andare reviewed at leastannually, but rapidchanges inCRC have prompted NCCN to revise andupdate theguidelinesmoreoften. In thealgorithm forapatient likethe oned escribed in Case 1( seeS idebar 1) with proven metastatic adenocarcinoma,N CCNs uggestss eparating patients into 3g roups: thosew ithl iver metastases,t hose with lung metastases,and thosewithmoredisseminate ddisease.
Forp atientsp resentingw ithl iver metastases at thef irst diagnosis, clinicians can select oneofseveral pathways.Treatment mightb egin with chemotherapy with ab iologic, andd ependingo np atient response, make ad ecisiona bout whethert o proceedw itht he primaryt umor removala nd liverr esection. Alternatively, theo ncologistm ight schedule surgeryt or emove thep rimary colonl esiona nd perhapsr emovet he liverl esion. Liverresection, if feasible,can also be scheduledfor alater time. Anothero ptioni sc olectomyf ollowedb yn eoadjuvant chemotherapyand then liverresection.
Patientsu nablet ou ndergo curative resectionm ustb ee valuated forsymptoms. Bleeding or obstructionmay be an indication fors urgery before chemotherapy.I nr elativelya symptomatic patients,proceedingwithchemotherapycan shrink theprimary tumora sw ella sm etastaticd isease.O ncologistsg enerally find that amongpatientswithhepatic metastases,approximately 70% arec onsideredu nresectable at diagnosis. However,as izable number of patients even with multiple lesionsm ay be able to undergo successfulsurgery.
Numerous studiesh ave examined surgical ratesi np atients with metastaticc olon cancerw ho have hads urgicalr esection, andt he 5-year survival rate (the pointa tw hich oncologists consider ap atient cured) ranges from 25%t on early6 0%, compared with patients with metastaticd isease whoh aven ot hadr esection; their5 -years urvivorship rate is between5 % and1 0%. [27] [28] [29] [30] [31] [32] [33] 
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Before combination chemotherapy and new treatment strategies were available, researchers identified several adverse prognostic factors that might preclude surgical resection. Prognosis is poorer when • the patients' original tumor is stage III or higher;
• patients have multiple lesions; • the lesions are larger than 3 cm, involve satellite lesions, or occur in both lobes of the liver; • metastases occur within the first 12 to 30 months; and/or • metastases occur outside the liver and primary colon site.
Prognostic factors, however, may be evolving with the introduction of modern chemotherapy approaches. 5 
■■ Approaches for Liver Metastases
Hepatic artery infusion (HAI) is the infusion of chemotherapy into the hepatic artery via a surgically implanted pump. Chemotherapy drugs can be injected periodically into the chamber of the pump, which then employs a gas-driven bellows to send chemotherapy by a hepatic artery catheter directly into the liver. Fluorodeoxyuridine (FUDR) has been the chemotherapy of choice for many years for HAI; compared with other agents, FUDR has the highest rate of extraction by the liver. Trials have compared HAI to systemic therapy with fluorouracil. [34] [35] [36] [37] [38] [39] [40] They have certain limitations and do not confirm a definitive survivorship benefit, but prior to the introduction of intravenous combination therapy, HAI produced the highest response rate seen in colon cancer: 50% to 60%. Since response rates with FOLFOX and FOLFIRI are similar to HAI, there may be a more limited role for HAI-delivered therapy.
Hepatic artery infusion has been tested for patients whose liver metastases have been resected. [34] [35] [36] [37] [38] [39] [40] These trials are also imperfect; however, they show without question that HAI recipients tend to experience less hepatic recurrence than those who did not.
Case 1: Patient Presentation
A 62-year-old nurse presented 10 months ago with a sigmoid colon lesion. She had a moderately differentiated, ulcerated 3 × 2 cm lesion (Stage II). After successful surgical resection, she received 6 months of adjuvant fluorouracil and leucovorin. Last month her carcinoembryonic antigen (CEA, used as a tumor marker for CRC) was elevated to 6.8 ng/mL. After seeing this individual, how would you proceed? Would you do a colonoscopy, a computed tomography (CAT) scan of the chest and abdomen and pelvis, a positron emission tomography (PET) scan, or an anti-CEA nuclear medicine scan?
A CAT scan is appropriate. This patient's rise in CEA in less than a year suggests the development of metastatic disease. Current surveillance strategies after surgery and adjuvant therapy for CRC are imperfect. Testing for CEA is the most widely used test, and it can be an early warning of metastases. Once it rises, the patient needs a full evaluation for metastatic disease. Colonoscopy is appropriate. In most individuals, the National Comprehensive Cancer Network (NCCN) 26 recommends colonoscopy 1 year after surgery to identify new polyps or a second primary tumor.
Although a PET scan would not be the first tool to evaluate metastatic disease, it can be helpful, particularly if further surgery to resect metastatic disease is being considered. The anti-CEA scan is available but is not widely used in the United States and certainly would not be a first choice.
The patient's colonoscopy was normal, but a CAT scan revealed 2 lesions (3 × 3 cm) in the right lobe of the liver. The PET scan confirmed the 2 lesions and found no other evidence of metastatic disease. The clinical team and patient chose surgical resection following chemother apy. The only opportunity to cure the person is with surgery, although the benefit of postoperative chemotherapy in this setting is unknown.
Sidebar 1
A regimen similar to FOLFOX (see below) that substitutes oral capecitabine for intravenous fluorouracil Experience with radiofrequency ablation (RFA,t he use of electrodest oh eata nd destroya bnormalt issue) in patients with hepaticm etastasis from CRCi si ncreasing. Open surgery, percutaneous RFA, andl aparoscopicR FA have been studied. Findings cannotconfirm that RFAiscurative-recurrencerates rangefromverylow to almost 50%depending on theunderlying presentation andnumberoflesions. [41] [42] [43] [44] [45] [46] [47] [48] If cure is thegoal, surgicalresectionremains theg oldstandard, butinpatientswho are notg ood surgical candidates, RFAmay be an option.C urrently, many surgical patients have ac ombination of surgical resection with concurrent interoperative RFAf or lesionst hatc annotb e resected;the cure rate is unknown.
Adam et al.e valuated thel ong-term survival of patients whoi nitiallyh ad inoperable colorectal liverm etastases that subsequentlyr espondedt os ystemicc hemotherapya nd eventually alloweds urgicalr esection. 8 They usedp rognostic factorso f outcomet oc reate am odel predictings urvivali nap r eoperative setting. In ac onsecutive series of 1,439p atientswithc olorectal liverm etastases from 1988 to 1999 at oneh ospital, 335( 23%) receivedinitial resection, and1 ,104 (77%)initiallyunresectable patients were treated with oxaliplatin-based or irinotecan-based chemotherapy,although12% of patients received fluorouraciland leucovorin alone. Afteradocumentedresponsetochemotherapy waso bserved, 138( 12.5%) of patients underwent secondary hepaticr esectionr esultingina3 3% 5-year survival.Ana verage of 10 coursesofchemotherapywereadministered preoperatively. The5 -years urvivalw as 48%f or thei nitials urgicalr esection group. Four preoperative risk factors( arectal tumor, an elevated CA 19-9,t umor larger than 10 cm,a nd 3o rm orem etastatic sites) predictedp oorero utcomef romthiss trategy. Neoadjuvant therapyr esults arec hangingt he wayo ncologists think about patients with metastaticdisease,introducing theconcepto fsurgicalresectionf or patients with previously unresectable disease. Survival expectancy at 5y ears forpatientswithriskfactors was also reported:1riskfactor, 23%to41%;2ri sk factors, 14%; and3 or 4riskfactors,0%to1 %. Althoughchemotherapycan produce acompleteresponseasmeasuredbyCAT scan,most patients will have residual tumorc ells visiblei np athology specimen;t herefore,wecan notsay at this time that neoadjuvantchemotherapy aloneiscurative.
With FOLFOX,t he maximumr eduction in tumors izei s usuallyseenwithin3months. Inaddition,longerperiodsof chemotherapya dministration can producel iver toxicity with nonalcoholics teatohepatitis,w hich can potentiallyincreasesurgical morbidity. Therefore, NCCN current ly recommendsa dministering approximately 3m onthso fc hemotherapy, then surgery, andt hena dditionalc hemotherapya fter surgery. Clinical trials arec urrently exploringt hisa pproach. Thes trategyi si dentical forpeoplewithisolatedlungmetastases.
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Advancedm etastaticd isease is usuallyt erminal. NCCN recommendst hatf or patients whop resent with,f or example, abdominalperitoneal disease, clinicians firstruleout obstruction. Chemotherapy is animmediate option in nonobstructingdisease, butother options(colonresection, colostomy,bypass, or stenting) must be considered if an obstructioni sp resent. Cases2a nd 3 demonstratesomeofthese principles (see Sidebar2 ). This patientactually wastreatedwith dailycontinuousvenousinfusion fluorouracilbut required adosereduction secondarytomucositis. Fortunately, he achieved apartial response and hisperformancestatusimprovedsignificantly. Although he is nowasymptomatic,his livermetastases have progressed.
Thekey pointinthiscaseisthatpatients with bulkydisease whoare chemotherapy-naïve and aresymptomatic poseclinicalchallenge.Someclinicians, concerned aboutthe patient'sperformancestatus, would optfor infusional fluorouracilorcapecitabine or fluorouraciland leucovorin. This wouldbeanappropriate choiceaccordingtothe NCCNguidelines.Thismay be thesolechance for treatment,however,and giving this individual thebestopportunity forresponse maybecritical. Although this patientresponded to infusional fluorouracil, that is notalwaysthe case.Someoncologist smightfavor combinationtherapyup front even with an impaired performance status, hoping forrapid response and improvedoverall outcome.
Case3
Twoyears ago, a70-year-old male underwentarighthemicolectomyfor astage II coloncancer and did notreceive adjuvant therapy. HisCEA is now100 ng/mL, and hischemistries arenormal.Despiteanexcellentperformancestatus, he has lung and livermetastases.Inthiscase, FOLFOXorFOLFIRIwith bevacizumab wouldbefavored by most oncologists as first-line therapy.
Single-agentfluorouracilwas themainstayoftreatment forCRC fordecades. Advances in thetreatment of CRCweregalvanized by Saltzand colleagues' 2000 NewEngland JournalofMedicine publication, 49 promulgating irinotecanas first-line therapy; concurrently,oncology's philosophy about therapyalsoshifted. In 1996,the FDAapprovedirinotecan, atopoisomerase Iinhibitor,asasecondline treatmentfor patients with metastatic CRC. Capecitabine, an oral fluoropyrimidine prodrug, wasapprovedin1998for metastatic breast cancer. In 2002, theFDA approvedanadditional indication-metastatic CRC-forcapecitabine. Capecitabineisconverted to fluorouracil by a3-enzymepathway including thymidine phosphorylase. Epidemiology,DiseaseProgression,and EconomicBurdenofColorectalCancer metastaticCRC in patients whoo ver-express EGFR.Cetuximab in combinationwithirinotecan is indicated forpatientswho are refractory to irinotecan-based chemotherapy.A sas inglea gent, cetuximabisindicated forpatientswho areintoleranttoirinotecan-based chemotherapy.
Grotheya nd colleagues analyzed data from 7p hase 3t rials (N =3187) in advanced CRCt oc omparet he proportion of patients receiving fluorouracil-leucovorin,irinotecan,and oxaliplatin administeredovertimewithmedianoverall survival (OS), usingaweightedanalysis. 50 They reported median OS correlated significantlyw itht he percentageo fp atientsw ho receiveda ll 3d rugs (but no biologics) in thec ourse of theird isease.I td id notc orrelate with thep ercentageo fp atientsw ho receiveda ny second-linetherapy.The use of combinationtherapies as first-line therapywas associated with an improvement in mediansurvival of 3.5m onths( 95%c onfidenceinterval[ CI], 1.27-5.73m onths; P =0.0083).T his representedad ramatics hift in survivorship from roughly13% to nearly 22%and in median survivorship at 2years.Their conclusion:the 3activedrugs should be available to allappropriate patients with advanced CRCtomaximizeOS. They also proposed thatOSisnot themost appropriate endpoint to assess theefficacyofafirst-linetreatment in CRC.
An updated report including4a dditionalp hase 3t rials( for at otal of 11 studies, N=5,768) validated theinitial analysis. 51 It confirmed thatt he percentage of patients with advanced CRC receiving 3d rugs during thec ourse of theird isease were likely to have longer OS.Again,the researchers gathe reddataonexposure to fluorouracil/leucovorin,irinotecan,and oxaliplatin.They concludedthatastrategyofmakingall active agents available to patients with advanced CRCappears to be more importantthan theu se of an individual therapy, andt hatc ombination therapy should remain thestandardofcarefor first-line treatment.
■■ TheTreatment Continuum
Cliniciansnow have more optionsfor treatingpatientswithCRC. This treatmentc ontinuumd efines as trategic approach fore ach patient. It encourages considerationo fa ll available treatment optionsand regimensequencesa crossm ultiplelines of therapy, creatinga ne arly plan fore achp atient to extend survival while minimizing side effects. Flexibility is crucial, too, so patients whoe xperienceo xaliplatin neurotoxicity, fore xample,c an be shifted to adifferentbut equallyeffectiveregimen.Thisreplaces the" treata sy ou go"a pproachu sedh istorically. Thet reatment continuumconceptisconsistentwiththe currentN CCNguidelinesfor metastaticCRC treatmentand puts theguidelinesinthe context of patientbenefits.
Safety andefficacyare emphasized as researchers have examined noto nlyd ifferent drugs, buta lsod ifferent administration techniques.F or example, in Europe,t here is traditionallym ore emphasis on continuous infusionf luorouracil; this regimen is believed to be safe, more efficacious, andm orec onducive to combinationt herapy.T hisb eliefl ed to thed evelopment of infusionr egimens, includingF OLFOXa nd FOLFIRI. In the United States,r esearchers andc linicianse mphasized bolus therapy. Thee vidence, however, nowi ndicates continuous intravenous infusion( CIV) is clearlysafer. 52 TheM eta-analysis Groupi nC ancerc onducted am etaanalysis of all randomized trials (N =1,219)t hatc ompared fluorouracilb olus with CIV, includingt oxicities, especially grades 3to4anemia, thrombocytopenia,leukopenia, neutropenia, nausea/vomiting, diarrhea,m ucositis,a nd hand-foots yndrome. They foundthatfluorouracilbolus wasmorelikelytocause hematologict oxicity, mainlyn eutropenia (31% with bolusv ersus4 % with CIV; P <0.0001) butless likely to be associated with handfoot syndrome (13% with bolusversus 34%withCIV; P <0.001). Theo ther nonhematologic toxicitiesd id notd iffer significantly betweengroups. Independent prognostic factorswereage,gender, andperformance status fornonhematol ogic toxicities; they were performances tatusa nd treatmentf or hematologict oxicities andage,gender,and treatmentfor hand-footsyndrome.
Saltze ta l. showed that irinotecan prolongs survival in CRC patients. In an intention-to-treat analysis,t reatment with irinotecan, fluorouracil,a nd leucovorin resulted in significantly longer progression-free survival (median, 7monthsversus4.3 months; P =0.004), ahigherrateofconfirmed response(39%versus21%; P <0.001), andl ongero verall survival (median,1 4.8m onths versus 12.6 months; P =0.04) thani rinotecan aloneo rf luorouracil andl eucovorin.R esults fori rinotecan alonew eres imilar to thosefor fluorouracil andleucovorin.Onthe basisofanalysis of adversee vents,a ddingi rinotecan to ther egimen of fluorouracil andleucovorin didnot compromisethe qualityoflife.
As econdt rial also examined thee fficacyo fi rinotecan and fluorouracil to treat3 87 previously untreatedp atients. 53 They were randomly assigned to irinotecan plus infusionfluorouracil andl eucovorin (N =199)o ra ni nfusionfluorouracil-leucovorin combinationa lone (N =188). Investigatorsc ould prescribea once-weekly or every-2-weekst reatment cycle. Ther esponse rate wassignificantlyhigherinpatientsinthe irinotecan group than in thosei nt he no-irinotecan group( 49%a so pposed to 31%; P <0.001), as wast ime-to-progression( median 6.7a s opposedt o4 .4 months; P <0.001). Overall survival wasa lso higher (median1 7.4asopposed to 14.1 months). Patientsreceivingirinotecan were more likely to develops omegrade 3and 4 toxiceffects, butdid so in apredictable manner.Adverse events were reversible, noncumulative, andmanageable. Theinvestigators suggested thatthe combinationtherapy be considered as a referencefirst-linetreatment formetastaticCRC.
Evolving First-Line Treatments
Goldberg et al.l ooked at 3d ifferent2 -drugc ombinationsi n patients with advanced metastaticC RC whow erep reviously untreated. Thei nvestigators accrued7 95 patients betweenM ay 1999 andA pril 2001.F OLFOXw as associated with am edian timeto-progressiono f8 .7 months,r esponser ateo f4 5%,a nd median survival time of 19.5 months.T hese resultsw eres ignificantlysuperior to all endpointsobservedfor IFL(6.9months, 31%, and1 5m onths, respectively) andf or time-to-progression andr esponsef or IROX (6.5 months,3 5%,a nd 17.4 months, respectively).T he FOLFOX regimen's adversee vent profilew as significantlybetterinterms of severe nausea, vomiting, diarrhea, febrileneutropenia,and dehydratio n. It was, however, associated with more sensoryneuropathyand neutropenia.Thus, theinvestigators foundt he FOLFOX regimena ctivea nd comparatively safe. In addition to supportingF OLFOXa sf irst-linet reatment form etastaticC RC,t he irinotecan/oxaliplatin regimeni sa n appropriate alternativefor fluorouraci l-intolerant individuals.
In Europe,t he FOLFOX andF OLFIRI infusions chedules were both used. An Italian research groupc ompared FOLFIRI with FOLFOX4i np reviously untreated patients (N =360)w ith advanced CRC. Overallr esponser ates were 31%i na rm Aa nd 34%i na rm B. Median time-to-progression, duration of response, andoverall survival were similari nb otha rms. Patients in armAr eported more alopecia andg astrointestinal disturbance; thosei na rm B experiencedmorethrombocytopeniaand neurosensorial adverse effects. Serioustoxicitywas uncommon forbothregimens. Both therapiesa re equally effectivea sf irst-linet reatments, although theirtoxicityprofilesdiffer.
Tournigand etal. randomized patients to FOLFOX6orFOLFIRI andallowed crossovertothe otherregimen afterdisease progression. 56 In armA,1 09 patie ntsreceivedFOLF IRIand 81 of the se patients were treatedwithsecond-lineFOLFOXuponprogression. In armB,111 patients receivedFOLFOXand 69 of thesepatients were treatedwithsecond-lineFOLFIRI upon progression. Median survivalsweresimilar in thearms: 21.5 months in armAversus 20.6 months in armB.Mediansecondp rogression-free survival was1 4.2m onthsi na rm Av ersus1 0.9m onthsi na rm B. Firstline responser ates were similar, 54%a nd 56%, respectively. Grade3 /4 mucositis, nausea/vomiting, andg rade 2a lopecia were more frequentw ithF OLFIRI,a nd grade3 /4 neutropenia andn eurosensoryt oxicityw erem oref requentw ithF OLFOX6. This triali ndicates thatt he sequence usedi si rrelevant; overall survivorship of about2 1m onthsi se xpected with either approach. Either regimeni sa na p propriatep latformo nw hich to buildother treatment approaches. Thedifferencesintoxicities mayguide treatment choice.
EnterOralAgents
Twor andomizedp hase 3t rialsc ompared oral capecitabine monotherapyw itht he Mayo regimeno fi ntravenous bolus fluorouracil andl eucovorin (dailyf or 5d ays) as first-line therapyi np atientsw ithn ewlyd iagnosed metastaticC RC. 57, 58 Data obtained from each trialw erep ooled. .B yo bservation, cliniciansh ave determined thatp eoplei nt he United States do nott oleratec apecitabinei nt he samed oses that Europeans do.O ne theory is that theh eavily fortifiedd iet in theU nited States isf olate-rich,a ccountingf or increasedf luoropyrimidine toxicity.
Studieso fc ombinationso fc apecitabinei dentical to those usingF OLFOXa nd FOLFIRIh ave been reported.B uilding on theirp reviousw ork, Grotheye ta l. designed ar andomized phase2t rial whereby patients receivede itherX ELOX (N =80) or XELIRI (N =77) andu ponp rogressionw eret hen treated with thealternative regimen: XELIRI (N =34) or XELOX (N =31). 5m onthsv ersus1 8.8m onths, respectively) as wasi nitial responser ate( 51%v ersus4 1%,r espectively) andp rogressionfree survival (6.2 months versus 7.1months, respectively).
Enterthe Biologics
Then extm ajor advancement forC RC wast he introduction of biologics, af ormo ft argeted therapy. Bevacizumabi sa na ntibody directed againstV EGF, as oluble proteini nstrumental in angiogenesis. 61 Useo ft argeted therapiesi nc ombination with cytotoxica gentsi se xpanding optionsw ithin thel ines of therapy.
To determine whethert he addition of bevacizumabt oI FL improves survival amongmetastatic CRCpatients, Hurwitzand colleagues 62 randomly assigned 813patientsin ablindedfashion with previously untreated metastaticC RC to receive either IFL (the standard at thet ime) plus bevacizumab( N=402) or IFL plus placebo( N=411). At hird armi ncludedf luorouracil and leucovorin plusb evacizumab.A fter ap redetermined interim safety analysisc onfirmed thes afetyo ft he IFLr egimen with bevacizumab, thef luorouracila nd leucovorin armo ft he trial wasdiscontinued. Patientsreceived5mg/kg bevacizumabevery 2w eeks.T he primarye ndpointw as overall survival,a nd secondary endpointsw erep rogression-free survival,r esponser ate, duration of response, safety, andquality of life.
Adding bevacizumabt oi rinotecan plus bolusf luorouracil andl eucovorin (IFL)r esulted in as ignificanta nd clinically meaningfuli mprovement in survival (20.3v ersus1 5.6m onths; P <0.001). Mediand urationo ft herapy was9 .3 months in the armr eceiving irinotecan plusf luorouracil andl eucovorin plus bevacizumaba nd 6.4m onthsi nt he armr eceiving irinotecan plusf luorouracil andl eucovorin.T he discontinuation rate due to adverse events was8 .4%i nt he irinotecan plusf luorouracil andl eucovorin plusb evacizumab arma nd 7.1% in thei rinotecan plusf luorouracil andl eucovorin arm. Thei ncidence of anyg rade 3o r4a dverse eventsw as approximately 10% higher amongp atientsr eceiving IFLp lusb evacizumab than amongt hose receiving IFLp lusp lacebo;t his wasl argely duet op atientsr eceiving theI FL plus bevacizumabr egimen having higher incidences of grade3h ypertension( 11%v ersus 2.3%), as well as grade4d iarrhea( 32.4%v ersus2 4.7%)a nd leucopenia( 37%versus3 1.1%). 62 In an abstract presentingas ubsequents ubgroupa nalysis, Hedricketal. 63 looked at use of irinotecan plus bolusfluorouracil andl eucovorin plusb evacizumab followed by oxaliplatin second-linet herapy.T heyf ound thati rinotecan plusb olus fluorouracil andl eucovorin plus bevacizumabf ollowedb y oxaliplatin second-linec an prolong survival to 25.1 months. This subset analysis also suggests thatat reatment strategy incorporatinga ll active agents over thec ourseo fd isease optimizeso verall survival.E xposingp atientst om orea ctive drugs, nowi ncluding biologics, mayp ushm edian survivorship evenfarther.
TheE astern CooperativeO ncologyG roup sponsored at rial forC RC patients whop rogressed aftert herapy with either fluorouracil or irinotecan plus fluorouracil. 64 Patients were randomized to receive (1)b evacizumab plusF OLFOX4 or (2)F OLFOX4 aloneo r( 3) bevacizumaba lone.R esponser ate, progression-free survival,a nd overalls urvivalw erei mproved when bevacizumabw as addedt oF OLFOX. Thea dditiono f second-linebevacizumab 10 mg/kgevery 2weeks to FOLFOX4 significantlyimprovedmedian overall survival from 10.7 to 12.5 months.Asasinglea gent, however, bevacizumabhad minimal, if any, activity andtherefore is notrecommendedasatherapeutic choice outside theclinicaltrial.
Ar andomizedp hase 2t rial by Hochs tere ta l. added bevacizumabt oo xaliplatin combinationc hemotherapyi n patients with metastaticCRC. 65 This randomized studyassesses thesafetyand tolerability of each of 3o xaliplatin plus fluoropyrimidine regimens (bolus,i nfusional, or oral fluoropyrimidine) aloneinTREE1,and with bevacizumabinTREE2.Regardless of thechemotherapyemployed, adding bevacizumabimproved the responserate. Thesedatawithbevacizumab in coloncancerare consistent across trials and across chemotherapy regimens.T he trialbyHochster et al.alsosuggested thatthe bolusfluorouracil/ oxaliplatin regimeni si nferior forp atientsw itha dvancedc olon cancerand cannotberecommended. 65 Cliniciansn eedt om onitor bevacizumabf or itsp otential adverse events.There is ariskofbleeding, whichoften manifests as mildepistaxis.The risk of venousthromboembolismdoesnot differb etween theg roupsw ho receivedb evacizumab andw ho didnot,soprevioushistory of venousthromboembolismdoesnot precludei ts use.B evacizumab mayb ea dministeredt op atients whoa re anticoagulatedf or venous thrombosis.P roteinuriai s aconcern, as is hypertension,and must be monitored. Themost recent warningf or bevacizumabalerts clinicianstothe possibilityo fr eversible posterior leukoencephalopathy (RPLS),ac ondition similart ow hati sa ssociatedw ithm alignanth ypertension or eclampsia during pregnancy. Evenm ildh ypertensiono ra change in blood pressure( e.g.,from90/60 to 120/85),can result in RPLS andwill requirediscontinuing bevacizumab.
66
Theriskofgastrointestinalperforation secondarytobevacizumabisrare, butreal andpotentiallylifethreatening. It hasbeen seen across trials.E pisodesw itho rw ithout intra-abdominal abscesses have occurred throughout treatment (i.e., they did notc orrelate with duration of exposure). Ty picalp resentation wasr eporteda sa bdominal pain associated with symptoms (e.g., constipation andv omiting).B evacizumab therapys hould be permanentlyd iscontinuedi np atientsw ithg astrointestinal perforation.
Wound-healingc omplication (wound dehiscence) is also possible andisanimportant considerationinpatientsundergoing surgery. Becauseo fi ts long half-life, patients receiving bevacizumab-containingr egimensm ustb eb evacizumab-free foram inimumo f 6w eeks before surgery. Ther isko f arterial thromboembolismisaconcern, particularly forthe elderly with ap revioushistory of arterial thromboembolism, such as cardiovasculara ccident, myocardial infarction,t ransient ischemic attacks, or angina.
Oneofthe most significantfindingsinmoderncoloncancer therapyisthatchemotherapycompared with best supportive care (BSC)i ss uperior even when toxicity is considered.T wo trials have also examined irinotecan as second-linet herapy. 67, 68 AB ritish studyc ompared irinotecan to BSCp rospectively; 279 patients with metastaticC RC whoh ad failed fluorouracil therapyw erer andomized2 :1 to receive either BSCp lust reatment with irinotecan 350mg/m 2 every 3weeks,orBSC alone. In the BSCg roup,1 4% of patients were still alive at 1y earc ompared with the3 6% of patients alive at 1y eara fter treatmentw ith irinotecan ( P =0.001). 67 Patientsr eceiving irinotecan liveds ignificantlyl ongerwithoutp erformance status deterioration; and deteriorationi nq uality of life (50% reductionf romb aseline) occurred significantlyl ater in thei rinotecan-treated patients than in controls.
Rougier andcolleaguesevaluated 101patientsrandomizedto receive 1of3second-lineregimens 2), respectively. Theser esearchers determinedt hats econdline treatmentw ithi rinotecan/LV5FU2, oxaliplatin/LV5FU2, or irinotecan/oxaliplatin controls tumorg rowthw ell, increases survival,a nd is safe. Thei ntention-to-treat objectiver esponse rates(ORRs)were11.4% (95% CI,3.2-26.7),21.2% (95% CI,9.0-38.9), and1 5.2% (95% CI,5 .1-31.9),respectively, in the3arms. Tumorgrowthcontrol was ≥ 60%for all3combinations.
Cetuximab
Cetuximabi sam onoclonala ntibodyt hats pecificallyb locks EGFR.C unninghame ta l. examined cetuximab'se fficacy in combination with irinotecan with that of cetuximabalone in metastaticCRC refractory to irinotecan. 69 Patients(N=329)whose CRCprogressed during or within 3monthsoftreatment with an irinotecan-based regimenwererandomizedtoreceive cetuximab plus irinotecan (N =218)o rc etuximab monotherapy( N=111). Thec ombination-therapy groupw as significantlym orelikelyt o respond thant he cetuximab-aloneg roup (22.9% versus 10.8%; P =0.007). Median time-to-progressionw as also significantly greateri nt he combinationt herapy group. Thea dditiono fi rinotecan increasedt oxicity( i.e.,d iarrheaa nd neutropenia)a s expected.Thus, cetuximab'sactivityalone (unlikethatofbevacizumabalone)orincombination with irinotecan wasdetermined to be significant. Because this workisfromphase 2trials, we do nothave survivor statistics forcetuximab.
Cetuximab'sc omplete prescribingi nformation indicatest hat cetuximabi sa ppropriately usedi nt umorst hats tain positive forE GFR; however, neitherE GFR-stainingn or thep ercentageo fc ells expressingE GFRc orrelate with responser ate. 70 Furthermore, thereare nowdatatosupport theuse of cetuximab forEGFR-negative patients. 71 With cetuximaba nd otherE GFR-targeted therapies, skin toxicity maya ctuallyb eas urrogate fore fficacy. Trials have shownthatthose whod evelop the most pronounced acne-form rash arethose whoare most likelytobenefit. 72 Because cetuximaba nd bevacizumabh ave differentt oxicity profiles andbiologictargets,theoretically it wouldbeappropriate to look at cetuximaband bevacizumabcombinations. Arandomized phase2t rial examinedc etuximab andb evacizumab with or without irinotecan. 73 Ther esponser atew as significant forp atientsr eceiving second-lineo rt hird-linet reatmenta nd superior forpatientstreated with theirinotecan-cetuximab-bevacizumabc ombination (38%,8 .5 months time-to-progression, compared with 23%t ime-to-progressionf or cetuximaba nd bevacizumab).
Thesed atah ave stimulated thed evelopment of additional randomized phase3trials.I ti sn ow cleart hats econd-line and third-line treatmentcan extend thebenefit of first-line treatment. It increasesresponserates across treatment lines, extendsoverall survival usingcombinationso fcytotoxic andtargetedtherapies, andappears to sensitizepreviouslyrefractorytumors.
Thec hallenge of thesen ew regimens is thatt oxicityc an be significanta nd patients grow wearyo fo ngoing treatment. To address this problem, researchersa re nowe xamining" stop andg o" approaches. Onep articulars trategyd rops theo xaliplatin afteradefined period of time,introducing it againatdisease progression. 74 Initialstudies suggestdoing so is safeand uncompromisingofthe overall strategy.Thissuggeststhatatmaximum response, patients mightb ea ffordede itherc ompleteb reaks in therapyo rless intensivetherapy untilthe diseasep rogresses. At progression, combination therapyc an be reintroduced.T his mayalleviate toxicitiesand reduce costs.
Themanychoicesf or advanced metastaticCRC arereflected in theN CCNg uidelines. NCCN hasi dentifiedc hoices for people whoc annott oleratei ntensivet herapy with agents such as capecitabine or infusionalfluorouracil. Forthe less fit patient, it is importanttoweigh theriskoftherapy,including combination therapy, with then eedt oa chieve theb estr esponsea sa n effort to most effectivelya chieve disease controla nd improved performancestatus.
MostRecentApproval:Panitumumab
TheF DA approvedp anitumumabi nS eptember2 006( just a week before thes ymposium upon whicht he supplement is based).Panitumumabbinds specificallytoEGFRonnormaland tumorc ells,c ompetitivelyinhibitingligand-binding. Afterp anitumumabb inds to EGFR,l igand-mediated receptors itea utophosphorylation is inhibited,a si sa ctivationo fr eceptor-associated kinases. Cell growth is inhibited, andapoptosis is induced. Proinflammatorycytokines andvascularepithelialgrowthfactor production decrease. 75 Panitumumabd iffersf romc etuximab, whichisachimericantibody, in thatitisafully humanmonoclonalantibody. Some researchers believe thatthere is less risk for infusionreactions with fullyhuman monoclonal antibodies.
Panitumumab'sp ivotal trialw as ap hase 3m ulticenter,r andomizedc ontrolledt rial.P eeters andc olleaguesc ompared the effect of panitumumab6mg/kg every 2weeks andBSC (N =231) with BSCalone (N =232)inpatientswithprogressivemetastatic CRCd uringo rf ollowing treatmentw ithf luoropyrimidine,i rinotecan,a nd oxaliplatin. 75, 76 Allp atientsh ad at least1 %t umor cell membranep ositives tainingf or EGFR by centrallyr ead immunohistochemistry. Tumorr esponses were determineda t weeks8 ,1 2, 16,2 4, 32,4 0, 48,a nd every1 2w eeks thereafter untilprogression. Responses were confirmed more than 4weeks afterc riteriaw eref irst met. This design is somewhat flawed in that people were allowed crossovera nd many patients had crossoverb eforet he firsta nalysis. Patientsr eceiving panitumumabplusBSC showed asignificantimprovement in progressionfree survival,w itha4 6% lowerr elative progressionr atev ersus theB SC-alone group. At as earlya s8w eeks into treatment, a higher percentage of panitumumabp lusB SC-treated patients were alive without progressionthaninthe BSCgroup alone. This differencei nf avor of thep anitumumabp lusB SC groupv ersus theBSC groupalone continuedthroughweek32ofthe study.
■■ Conclusion
Clearly, many choicesare available to clinicianswho treatpatients whohave CRC. They will need to balance concerns about toxicityw itht hose about cost (see Table4 ). In thec omingm onths andyears,the resultsfromnumerousongoing clinical trialswill furtherrefineour choices. Theexperts at NCCN will continue to refineand update theirguidelinestoreflect thesechanges andto give patients thelongest andbestlifeafter adiagnosis of CRC.
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